http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 15 Oct 2024 08:05:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Board+Changes/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html <p><span data-silink="1" href="https://www.globenewswire.com/Tracker?data=xBndz-6f7xM6jxaxEV3-3WVqSH34wonfZMwRncUXOD5iYBmTFQjfuOdbo16ehoqH6wI-rHMeoqqaOUhji4JYcegZPPwztmlfPOJm5KdNDTgtyAIMfdolegsyf9CjAP39lwy_9t0WYVoN4qtM39owsMcAvq4xk2nbcBoO1M89lCZtorFCqood1zcQ4F4k-p_vOzvJ5UOxYC1MKR8xx4F08yIZb82PyD-SHyuWRThINVV3uoLYZ9k15Yu7rM4a6vtLI1UbkCsCCV-NnoFFKL0hWlrkYAO_0yvqVEy4i8WGpcJWOxSt_n1YKjPs5BW9f8dPsQu96dBqhWFsCrjnv5BCP1MUbKO-LaG0A3aW-iipdj-p8wMZ0Lm4jjroG9thJbU6" rel="nofollow" target="_blank">MaxCyte, Inc.</span>, (Nasdaq: MXCT) today announced the appointment of Cynthia Collins to the Company’s Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board’s compensation committee. Following her appointment, MaxCyte’s total Board of Directors will increase to 10 members.</p><p> </p><p align="justify">“I am pleased to welcome Cynthia to MaxCyte’s Board of Directors,” said Maher Masoud, President and CEO of MaxCyte. “Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to http://www.streetinsider.com/Corporate+News/Poseida+Therapeutics+%28PSTX%29+Appoints+Cynthia+Collins+to+its+Board/23834765.html Tue, 15 Oct 2024 08:05:51 -0400 CERT DMTKQ MXCT PSTX http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Press+Releases/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359 http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html <p> SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. </p><p> Led by a dedicated team of dermatologists, dermatopathologists and experienced laboratory and industry professionals, DermTech, LLC’s focus will be a renewed commitment to quality and customer support. The now-private company will remain in its state-of-the http://www.streetinsider.com/Business+Wire/DermTech+Completes+Transaction+for+Asset+Sale%3B+Operations+Continue+Under+New+Ownership+and+Management/23671352.html Fri, 30 Aug 2024 11:13:00 -0400 A.00157782 A.19658497 A.22194166 A.50100012 DMTKQ O.00053334 O.05948807 O.07579093 O.22801920 O.46180359